European Medicines Agency
The European Medicines Agency (EMA), headquartered in the Netherlands, plays a pivotal role in the pharmaceutical industry by ensuring the safety and efficacy of medicines across Europe. Founded in 1995, the agency has been instrumental in the evaluation and supervision of medicinal products, facilitating access to innovative therapies for patients. With a focus on human and veterinary medicines, the EMA collaborates with national regulatory authorities to uphold high standards in public health. Its unique position allows for streamlined processes in drug approval, making it a cornerstone of the European healthcare landscape. Notable achievements include the rapid assessment of COVID-19 vaccines, showcasing its agility in responding to public health emergencies. The EMA continues to lead in regulatory science, fostering innovation while safeguarding patient safety.
DitchCarbon Score
How does European Medicines Agency's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
European Medicines Agency's score of 27 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
European Medicines Agency's reported carbon emissions
In 2023, the European Medicines Agency (EMA) reported total carbon emissions of approximately 1,901,900 kg CO2e, with all emissions classified under Scope 3, specifically from business travel, which accounted for about 1,682,900 kg CO2e. This marks a significant increase from 2022, when total emissions were about 979,900 kg CO2e, with business travel contributing approximately 791,600 kg CO2e. The EMA's emissions data for previous years shows a consistent focus on business travel as the primary source of their carbon footprint. In 2021, emissions were about 178,500 kg CO2e, with business travel at 800 kg CO2e, and in 2020, total emissions were approximately 809,100 kg CO2e, with business travel contributing around 525,700 kg CO2e. Currently, the EMA has not set specific reduction targets or initiatives, nor do they have any climate pledges or commitments documented. The absence of Scope 1 and Scope 2 emissions data indicates a potential area for future reporting and improvement. The EMA operates independently without cascading emissions data from a parent organization, ensuring that their reported figures reflect their own operational impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | - | - | - | - |
| Scope 3 | 525,700 | 000 | 000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
European Medicines Agency is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
